**Supplementary Figure S1. LIMK in prostate cancer. A,** LIMK1 peptide was spotted on PVDF membranes at 50, 25 or 5 ng per spot, then blocked and blotted with LIMK1 antibody that had been left untreated or pre-incubated with 4 µg/ml LIMK1 or cofilin non-specific control peptide as indicated. In parallel, orthotopic LNCaP tumor samples were stained with LIMK1 antibody, without or with pre-incubation with the competing peptides. **B,** Graph of percentage disease-free patients versus months disease-free survival for patients without or with altered *LIMK1* expression as indicated. Data was from {Taylor, 2010 #9357} and analyzed via the cBio Cancer Genomics Portal {Cerami, 2012 #9360}. **C,** LNCaP cells were treated with 1 or 10 nM DHT for 24 hours and LIMK1, LIMK2 and α-Tubulin expression analyzed by western blotting. Graphs show combined data from three independent experiments ± SEM. **D,** LNCaP cells were treated with 1 nM DHT and 1 or 3 µM LIMKi for 24 hours and MMP-10, MMP-1 and α-Tubulin expression in cell lysates subsequently analyzed by western blotting.